Fulcrum Therapeutics (FULC) Institutional Ownership

89.83% of Fulcrum Therapeutics' stock is owned by institutional investors. Learn more on FULC's institutional investor holdings.

Of the 126 institutional investors that purchased Fulcrum Therapeutics' stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Braidwell LP ($4.13M), Suvretta Capital Management LLC ($3.63M), Adage Capital Partners GP L.L.C. ($2.59M), Siren L.L.C. ($2.35M), First Turn Management LLC ($1.89M), GSK plc ($1.79M), and Assenagon Asset Management S.A. ($1.69M).

Institutional investors have bought a total of 23,169,341 shares in the last 24 months. This purchase volume represents approximately $231.99M in transactions.

Of the 51 institutional investors that sold Fulcrum Therapeutics' stock in the last 24 months, the following investors and hedge funds have sold the highest volume of shares: RA Capital Management L.P. ($4.18M), ADAR1 Capital Management LLC ($1.19M), Royal Bank of Canada ($996.74K), Nantahala Capital Management LLC ($911.83K), Adage Capital Partners GP L.L.C. ($732K), Balyasny Asset Management L.P. ($480.04K), and Goldman Sachs Group Inc. ($402.13K).

Institutional investors have sold a total of 11,416,278 shares in the last 24 months. This volume of shares sold represents approximately $117.56M in transactions.